Valuation: Alcon

Market Cap 33.28B 29.23B 27.18B 24.95B 46.87B 3,205B 47.59B 323B 126B 1,576B 125B 122B 5,448B P/E 2026 *
31.2x
P/E 2027 * 24.5x
Enterprise Value 35.88B 31.51B 29.3B 26.89B 50.52B 3,455B 51.3B 348B 136B 1,699B 135B 132B 5,873B EV / Sales 2026 *
3.22x
EV / Sales 2027 * 2.95x
Free-Float
97.36%
Yield 2026 *
0.51%
Yield 2027 * 0.59%
Manager TitleAgeSince
Chief Executive Officer 60 2018-06-30
Director of Finance/CFO 58 2019-04-07
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 2018-06-30
Director/Board Member 63 2019-01-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33.28B
+0.99%-1.92%-34.52%-7.77% 85.56B
+0.11%-1.95%-5.74%-27.20% 13.71B
-0.27%+3.48% - - 10.04B
-0.34%-3.62%-27.30%+481.71% 1.81B
-4.61%-4.09%-41.27%-67.44% 1.4B
-3.40%-6.73%-41.44%-33.29% 801M
-1.34%-1.04%+3.11%-11.48% 787M
+1.39%-0.65%+43.04%-32.76% 759M
-1.87%+3.64% - - 685M
Average -0.93%-1.78%-14.87%+43.11% 12.84B
Weighted average by Cap. +0.49%-1.74%-29.93%-3.05%

Financials

2026 *2027 *
Net sales 11.14B 9.78B 9.1B 8.35B 15.68B 1,072B 15.92B 108B 42.2B 527B 41.8B 40.9B 1,823B 11.81B 10.37B 9.65B 8.85B 16.63B 1,137B 16.89B 115B 44.76B 559B 44.34B 43.39B 1,934B
Net income 1.08B 949M 883M 810M 1.52B 104B 1.55B 10.48B 4.1B 51.16B 4.06B 3.97B 177B 1.35B 1.18B 1.1B 1.01B 1.9B 130B 1.93B 13.07B 5.11B 63.79B 5.06B 4.95B 221B
Net Debt 2.59B 2.28B 2.12B 1.94B 3.65B 250B 3.71B 25.17B 9.83B 123B 9.74B 9.53B 425B 1.54B 1.35B 1.26B 1.15B 2.17B 148B 2.2B 14.94B 5.84B 72.94B 5.78B 5.66B 252B
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA